Neuburgh Advisers’s Anika Therapeutics ANIK Stock Holding History

Neuburgh Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$97K	Buy	+1,760	New	+$90.4K	﹤0.01%	799

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Neuburgh Advisers's ANIK Position: Q3 2019 in Review

Neuburgh Advisers opened a new position in Anika Therapeutics (ANIK) in Q3 2019: 1,760 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #799 among its holdings.

194 funds tracked by Wall St. Rank hold ANIK as of Q3 2019.

Neuburgh Advisers held 1,760 shares of Anika Therapeutics worth $97K as of Q3 2019.
Anika Therapeutics was a new Neuburgh Advisers position in Q3 2019.
Anika Therapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #799 holding.
194 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.